From bench to bed and back again: phage therapy of childhood Escherichia coli diarrhea

Annals of the New York Academy of Sciences

Volumn 1372, Issue 1, 2016, Pages 42-52

  Sarker, Shafiqul A ^a   Brüssow, Harald ^b  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

diarrhea; Escherichia coli; pediatric; phage therapy; T4 bacteriophage

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL PRODUCT;

ARTICLE; BACTERIOPHAGE; BIOLOGICAL THERAPY; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIA PHAGE T4; ESCHERICHIA COLI INFECTION; HOST RANGE; HUMAN; INFECTIOUS DIARRHEA; NONHUMAN; ORAL REHYDRATION THERAPY; PHAGE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS ISOLATION;

EID: 84978886315     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.13087     Document Type: Article

References (51)

1. Brown, E.D. & G.D. Wright. 2016. Antibacterial drug discovery in the resistance era. Nature 529: 336–343.
2. Rauch, M. & S.V. Lynch. 2012. The potential for probiotic manipulation of the gastrointestinal microbiome. Curr. Opin. Biotechnol. 23: 192–201.
3. Vandenheuvel, D., R. Lavigne & H. Brüssow. 2015. Bacteriophage therapy: advances in formulation strategies and human clinical trials. Annu. Rev. Virol. 2: 599–618.
4. Walsh, C.J., C.M. Guinane, P.W. O'Toole, et al. 2014. Beneficial modulation of the gut microbiota. FEBS Lett. 588: 4120–4130.
5. Sulakvelidze, A., Z. Alavidze & J.G. Morris, Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45: 649–659.
6. Sarker, S.A., T.H. Casswall, D. Mahalanabis, et al. 1988. Successful treatment of rotavirus diarrhea in children with immunoglobulin from immunized bovine colostrum. Pediatr. Infect. Dis. J. 17: 1149–1154.
7. Sarker, S.A., S. Sultana, G.J. Fuchs, et al. 2005. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics 116: e221–e228.
8. Brüssow, H. 2001. Phages of dairy bacteria. Annu. Rev. Microbiol. 55: 283–303.
9. Kaper, J.B., J.P. Nataro & H.L. Mobley. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2: 123–140.
10. Qadri, F., A.M. Svennerholm, A.S. Faruque, et al. 2005. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin. Microbiol. Rev. 18: 465–483.
11. Miller, E.S., E. Kutter, G. Mosig, et al. 2003. Bacteriophage T4 genome. Microbiol. Mol. Biol. Rev. 67: 86–156.
12. Tenaillon, O., D. Skurnik, B. Picard, et al. 2010. The population genetics of commensal Escherichia coli. Nat. Rev. Microbiol. 8: 207–217.
13. Yee, S.Y., N.Y. Fong, G.T. Fong, et al. 2006. Male-specific RNA coliphages detected by plaque assay and RT-PCR in tropical river waters and animal fecal matter. Int. J. Environ. Health Res. 16: 59–68.
14. Chibani-Chennoufi, S., J. Sidoti, A. Bruttin, et al. 2004. Isolation of Escherichia coli bacteriophages from the stool of pediatric diarrhea patients in Bangladesh. J. Bacteriol. 186: 8287–8294.
15. Bachmann, B.J. 1972. Pedigrees of some mutant strains of Escherichia coli K-12. Bacteriol. Rev. 36: 525–557.
16. Bourdin, G., A. Navarro, S.A. Sarker, et al. 2014. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb. Biotechnol. 7: 165–176.
17. Kelly, D., O. McAuliffe, R.P. Ross, et al. 2011. Development of a broad-host-range phage cocktail for biocontrol. Bioeng. Bugs 2: 31–37.
18. Bourdin, G., B. Schmitt, L. Marvin Guy, et al. 2014. Amplification and purification of T4-like Escherichia coli phages for phage therapy: from laboratory to pilot scale. Appl. Environ. Microbiol. 80: 1469–1476.
19. Harper, M.S., C. Carpenter, D.J. Klocke, et al. 2011. E. coli lipopolysaccharide: acute oral toxicity study in mice. Food Chem. Toxicol. 49: 1770–1772.
20. Sarker, S.A., S. McCallin, C. Barretto, et al. 2012. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 434: 222–232.
21. Zuber, S., C. Ngom-Bru, C. Barretto, et al. 2007. Genome analysis of phage JS98 defines a fourth major subgroup of T4-like phages in Escherichia coli. J. Bacteriol. 189: 8206–8214.
22. Denou, E., A. Bruttin, C. Barretto, et al. 2009. T4 phages against Escherichia coli diarrhea: potential and problems. Virology 388: 21–30.
23. Miller, E.S., E. Kutter, G. Mosig, et al. 2003. Bacteriophage T4 genome. Microbiol. Mol. Biol. Rev. 67: 86–156.
24. Chibani-Chennoufi, S., J. Sidoti, A. Bruttin, et al. 2004. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob. Agents Chemother. 48: 2558–2569.
25. Weiss, M., E. Denou, A. Bruttin, et al. 2009. In vivo replication of T4 and T7 bacteriophages in germ-free mice colonized with Escherichia coli. Virology 393: 16–23.
26. Bruttin, A. & H. Brüssow. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49: 2874–2878.
27. McCallin, S., S.A. Sarker, C. Barretto, et al. 2013. Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 443: 187–196.
28. Pound, M.W. & D.B. May. 2005. Proposed mechanisms and preventative options of Jarisch–Herxheimer reactions. J. Clin. Pharm. Ther. 30: 291–295.
29. Sarker, S., S. Sultana, G. Reuteler, et al. 2016. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4: 124–137.
30. Liberato, S.C., G. Singh & K. Mulholland. 2015. Zinc supplementation in young children: a review of the literature focusing on diarrhea prevention and treatment. Clin. Nutr. 34: 181–188.
31. Lamberti, L.M., C.L. Walker, K.Y. Chan, et al. 2013. Oral zinc supplementation for the treatment of acute diarrhea in children: a systematic review and meta-analysis. Nutrients 5: 4715–4740.
32. Qadri, F., A. Saha, T. Ahmed, et al. 2007. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Infect. Immun. 75: 3961–3968.
33. Barletta, F., T.J. Ochoa, E. Mercado, et al. 2011. Quantitative real-time polymerase chain reaction for enteropathogenic Escherichia coli: a tool for investigation of asymptomatic versus symptomatic infections. Clin. Infect. Dis. 53: 1223–1229.
34. David, L.A., A. Weil, E.T. Ryan, et al. 2015. Gut microbial succession follows acute secretory diarrhea in humans. MBio 6: e00381–e00415.
35. Wommack, K.E. & R.R. Colwell. 2000. Virioplankton: viruses in aquatic ecosystems. Microbiol. Mol. Biol. Rev. 64: 69–114.
36. Faruque, S.M., I.B. Naser, M.J. Islam, et al. 2005. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc. Natl. Acad. Sci. U.S.A. 102: 1702–1707.
37. Faruque, S.M., M.J. Islam, Q.S. Ahmad, et al. 2005. Self-limiting nature of seasonal cholera epidemics: role of host-mediated amplification of phage. Proc. Natl. Acad. Sci. U.S.A. 102: 6119–6124.
38. Wiggins, B.A. & M. Alexander. 1985. Minimum bacterial density for bacteriophage replication: implications for significance of bacteriophages in natural ecosystems. Appl. Environ. Microbiol. 49: 19–23.
39. Brüssow, H. 2103. Bacteriophage–host interaction: from splendid isolation into a messy reality. Curr. Opin. Microbiol. 16: 500–506.
40. Taniuchi, M., S.U. Sobuz, S. Begum, et al. 2013. Etiology of diarrhea in Bangladeshi infants in the first year of life analyzed using molecular methods. J. Infect. Dis. 208: 1794–1802.
41. Liu, J., F. Kabir, J. Manneh, et al. 2014. Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study. Lancet Infect. Dis. 14: 716–724.
42. Kotloff, K.L., J.P. Nataro, W.C. Blackwelder, et al. 2013. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case–control study. Lancet 382: 209–222.
43. Jin, D., C. Chen, L. Li, et al. 2013. Dynamics of fecal microbial communities in children with diarrhea of unknown etiology and genomic analysis of associated Streptococcus lutetiensis. BMC Microbiol. 13: e141.
44. Kassinen, A., L. Krogius-Kurikka, H. Mäkivuokko, et al. 2007. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24–33.
45. Rigsbee, L., R. Agans, V. Shankar, et al. 2012. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 107: 1740–1751.
46. Wright, A., C.H. Hawkins, E.E. Anggård, et al. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34: 349–357.
47. Mai, V., M. Ukhanova, M.K. Reinhard, et al. 2015. Bacteriophage administration significantly reduces Shigella colonization and shedding by Shigella-challenged mice without deleterious side effects and distortions in the gut microbiota. Bacteriophage 5: e1088124.
48. Maura, D., E. Morello, L. du Merle, et al. 2012. Intestinal colonization by enteroaggregative Escherichia coli supports long-term bacteriophage replication in mice. Environ. Microbiol. 14: 1844–1854.
49. Maura, D., M. Galtier, C. Le Bouguénec, et al. 2012. Virulent bacteriophages can target O104:H4 enteroaggregative Escherichia coli in the mouse intestine. Antimicrob. Agents Chemother. 56: 6235–6242.
50. Brüssow, H. 2005. Phage therapy: the Escherichia coli experience. Microbiology 151: 2133–2140.
51. Sack, D.A. 2013. A new era in the history of cholera: the road to elimination. Int. J. Epidemiol. 42: 1537–1540.